OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use (vol 34, pg 1287, 2020)

被引:0
作者
Frampton, James E. [1 ]
机构
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
关键词
D O I
10.1007/s40263-021-00828-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The article OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use, written by James E. Frampton, was originally published electronically on SpringerLink on 11 December 2020 without open access. After publication in volume 34, issue 12, page 1287-1298, AbbVie requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AbbVie. Therefore, the copyright of the article has been changed to (c) Springer Nature Switzerland AG 2020 and the article is forthwith distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
引用
收藏
页码:701 / 701
页数:1
相关论文
共 50 条
  • [21] Osimertinib as first-line therapy in advanced NSCLC: a profile of its use (vol 34, pg 351, 2018)
    Scott, Lesley J.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (01) : 50 - 50
  • [22] Fremanezumab in the prevention of migraine: a profile of its use
    Yvette N. Lamb
    Drugs & Therapy Perspectives, 2019, 35 : 592 - 600
  • [23] Erenumab in the prophylaxis of migraine: a profile of its use
    Emma H. McCafferty
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2019, 35 : 13 - 20
  • [24] Fremanezumab in the prevention of migraine: a profile of its use
    Lamb, Yvette N.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (12) : 592 - 600
  • [25] Erenumab in the prophylaxis of migraine: a profile of its use
    McCafferty, Emma H.
    Lyseng-Williamson, Katherine A.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (01) : 13 - 20
  • [26] Difelikefalin in pruritus associated with chronic kidney disease: a profile of its use (vol 38, pg 423, 2022)
    Lamb, Yvette N.
    DRUGS & THERAPY PERSPECTIVES, 2022, 38 (11) : 500 - 500
  • [27] Appropriate Use of Opioids for Chronic Pain (vol 102, pg 335, 2020)
    Roth, Alan R.
    Lazris, Andy
    Haskell, Helen
    James, John
    AMERICAN FAMILY PHYSICIAN, 2021, 103 (01) : 8 - 8
  • [28] Efficacy of Fremanezumab in Patients with Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA
    Spierings, E. L. H.
    Yeung, P. P.
    Blankenbiller, T.
    Ning, X.
    Yang, R.
    Ma, Y.
    Bigal, M.
    Aycardi, E.
    HEADACHE, 2018, 58 : 83 - 83
  • [29] Real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine: The Repose Study
    Ahmed, Fayyaz
    Gaul, Charly
    Martelletti, Paolo
    Carlos Garcia-Monco, Juan
    Adams, Aubrey Manack
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [30] Real-Life Use of OnabotulinumtoxinA for the Symptomatic Treatment of Chronic Migraine: The Repose Study
    Ahmed, Fayyaz
    Gaul, Charly
    Martelletti, Paolo
    Garcia-Monco, Juan Carlos
    Adams, Aubrey Manack
    CEPHALALGIA, 2017, 37 : 94 - 94